What is Levodopa-Benserazide?
Category: Prescription Drugs
Most popular types: Madopar Madopar dispersible Prolopa Show all
Levodopa is the precursor molecule to dopamine, an important neurotransmitter implicated in the underlying cause of Parkinson's disease. Benserazide is an additive which allows the levodopa to continue circulating in the body for longer.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Parkinson's disease | 101 | 115 | |
| Stiffness/spasticity | 12 | 8 | |
| Multiple system atrophy | 5 | 10 | |
| Tremor in hands | 3 | 3 | |
| Improve mobility | 2 | 0 | |
| Jerky movements | 2 | 8 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 8 | |
| Moderate | 32 | |
| Mild | 29 | |
| None | 59 |
Commonly reported side effects and conditions associated with Levodopa-Benserazide
| Side effect | Patients | Percentage |
|---|---|---|
| Constipation | 4 | |
| Jerky movements | 4 | |
| Nausea | 4 | |
| Tiredness | 4 | |
| Depressed mood | 2 | |
| Dizziness | 2 |
Why patients stopped taking Levodopa-Benserazide
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Doctor's advice | 8 | |
| Other | 7 | |
| Did not seem to work | 4 | |
| Personal research | 2 | |
| Side effects too severe | 2 | |
| Change in health plan coverage | 1 |
Duration
Stopped taking Levodopa-Benserazide
| Duration | Patients | Percentage |
|---|---|---|
| 1 - 6 months | 3 | |
| 6 months - 1 year | 5 | |
| 1 - 2 years | 7 | |
| 2 - 5 years | 5 | |
| 5 - 10 years | 2 |
What people switch to and from
Patients started taking Levodopa-Benserazide after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Carbidopa-Levodopa (Sinemet) | 2 | |
| Levodopa-Benserazide (Madopar) | 2 | |
| Carbidopa-Entacapone-Levodopa (Stalevo) | 1 | |
| Carbidopa-Levodopa CR (Sinemet CR) | 1 | |
| Ropinirole (Requip) | 1 |
Patients stopped taking Levodopa-Benserazide and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Carbidopa-Levodopa (Sinemet) | 6 | |
| Carbidopa-Entacapone-Levodopa (Stalevo) | 2 | |
| Levodopa-Benserazide (Madopar) | 2 | |
| Pramipexole (Mirapex) | 1 |
Last updated: